Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.
Tacrolimus hydrate (FK506) reduces myasthenic symptoms due to its immunosuppressive properties. We studied the therapeutic effects of FK506 and noted improvement in 7 of 13 myasthenic patients on the clinical muscle test (myasthenia gravis, MG score). Two other patients with relapsing ocular symptoms improved. We also examined patient sensitivity to FK506, but could not predict such sensitivity before FK506 treatment in the present study.
Wakata
Nobuo
N
Fourth Department of Internal Medicine, Toho University School of Medicine, 2-17-6 Oohashi, Meguro-ku, Tokyo 153-8515, Japan. waka@oha.toho-u.ac.jp
Saito
Toyokazu
T
Tanaka
Sachiko
S
Hirano
Toshihiko
T
Oka
Kitaro
K
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D009460:Neurologic Examination / Q000187:drug effects; D018579:Patient Selection; D011239:Prednisolone / Q000627:therapeutic use; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013934:Thymectomy; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D011239:Prednisolone; D016559:Tacrolimus